Inozyme gets Fast Track status for candidate for rare calcification condition

The U.S. FDA has granted Inozyme Pharma (NASDAQ:INZY) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency.
The company noted it hopes to have an agreement with regulators on a pivotal trial design by the end of the year.
In April, Inozyme released promising topline results from an ongoing phase 1/2 trial in adults showing clinical improvements were observed in vascular pathology, visual function, and patient reported outcomes.
ABCC6 Deficiency is characterized by progressive calcification in the eyes, skin, and arteries.